TY - JOUR
T1 - HOLA COVID-19 Study
T2 - Evaluating the Impact of Caring for Patients With COVID-19 on Cancer Care Delivery in Latin America
AU - HOLA COVID-19 Study Group
AU - Bernabe-Ramirez, Carolina
AU - Velazquez, Ana I.
AU - Olazagasti, Coral
AU - Bergerot, Cristiane Decat
AU - Bergerot, Paulo Gustavo
AU - Cruz, Jose Corona
AU - Riano, Ivy
AU - Adaniel, Christina
AU - Ramirez, Francisca
AU - Anampa, Jesus
AU - Cajina, Carmen
AU - Mena, Evelin
AU - Gracia, Elias
AU - Menendez, Alvaro
AU - Idrovo, Henry
AU - Bezares, Raimundo
AU - Fernandez, Omar Orlando Castillo
AU - Duque, Liseth
AU - Corrales-Rodríguez, Luis
AU - Ramos, Glenda
AU - Kihn-Alarcón, Alba J.
AU - Schlam, Ilana
AU - Bruno, Ximena
AU - Umanzor, Gerardo
AU - Castro, Jenny Lissette
AU - Losco, Federico
AU - Ubillos, Luis
AU - Richardet, Eduardo
AU - Soto-Perez-de-Celis, Enrique
AU - Duma, Narjust
N1 - Publisher Copyright:
© 2022 by American Society of Clinical Oncology
PY - 2022
Y1 - 2022
N2 - PURPOSE The HOLA COVID-19 study sought to evaluate the impact of COVID-19 on oncology practices across Latin America (LATAM), challenges faced by physicians, and how practices and physicians adapted while delivering care to patients with cancer. METHODS This international cross-sectional study of oncology physicians in LATAM included a 43-item anonymous online survey to evaluate changes and adaptations to clinical practice. Multivariable logistic regression analyses were used to evaluate the association of caring for patients with COVID-19 and changes to clinical practice. RESULTS A total of 704 oncology physicians from 19 countries completed the survey. Among respondents, the most common specialty was general oncology (34%) and 56% of physicians had cared for patients with COVID-19. The majority of physicians (70%) noted a decrease in the number of new patients evaluated during the COVID-19 pandemic when compared with prepandemic, and 73% reported adopting the use of telemedicine in their practice. More than half (58%) of physicians reported making changes to the treatments that they offered to patients with cancer. In adjusted models, physicians who had cared for patients with COVID-19 had higher odds of changing the type of chemotherapy or treatments that they offered (adjusted odds ratio 1.81; 95% CI, 1.30 to 2.53) and of delaying chemotherapy start (adjusted odds ratio 2.05; 95% CI, 1.49 to 2.81). Physicians identified significant delays in access to radiation and surgical services, diagnostic tests, and supportive care. CONCLUSION The COVID-19 pandemic has significantly disrupted global cancer care. Although changes to health care delivery are a necessary response to this global crisis, our study highlights the significant disruption and changes to the treatment plans of patients with cancer in LATAM resulting from the COVID-19 health care crisis.
AB - PURPOSE The HOLA COVID-19 study sought to evaluate the impact of COVID-19 on oncology practices across Latin America (LATAM), challenges faced by physicians, and how practices and physicians adapted while delivering care to patients with cancer. METHODS This international cross-sectional study of oncology physicians in LATAM included a 43-item anonymous online survey to evaluate changes and adaptations to clinical practice. Multivariable logistic regression analyses were used to evaluate the association of caring for patients with COVID-19 and changes to clinical practice. RESULTS A total of 704 oncology physicians from 19 countries completed the survey. Among respondents, the most common specialty was general oncology (34%) and 56% of physicians had cared for patients with COVID-19. The majority of physicians (70%) noted a decrease in the number of new patients evaluated during the COVID-19 pandemic when compared with prepandemic, and 73% reported adopting the use of telemedicine in their practice. More than half (58%) of physicians reported making changes to the treatments that they offered to patients with cancer. In adjusted models, physicians who had cared for patients with COVID-19 had higher odds of changing the type of chemotherapy or treatments that they offered (adjusted odds ratio 1.81; 95% CI, 1.30 to 2.53) and of delaying chemotherapy start (adjusted odds ratio 2.05; 95% CI, 1.49 to 2.81). Physicians identified significant delays in access to radiation and surgical services, diagnostic tests, and supportive care. CONCLUSION The COVID-19 pandemic has significantly disrupted global cancer care. Although changes to health care delivery are a necessary response to this global crisis, our study highlights the significant disruption and changes to the treatment plans of patients with cancer in LATAM resulting from the COVID-19 health care crisis.
UR - http://www.scopus.com/inward/record.url?scp=85125801326&partnerID=8YFLogxK
U2 - 10.1200/GO.21.00251
DO - 10.1200/GO.21.00251
M3 - Artículo
C2 - 35245084
AN - SCOPUS:85125801326
SN - 2378-9506
VL - 8
JO - JCO Global Oncology
JF - JCO Global Oncology
M1 - e2100251
ER -